5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-13-methoxy-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one | 902749-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-13-methoxy-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
• CAS: 902749-51-3
• 化学式: C₁₈H₁₃N₃O₄S
• 分子量: 367.385
• InChiKey: MCJLPWIVNKXWIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-13-methoxy-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 C₁₇H₁₁N₃O₄S
  参考文献：
  名称：

  Tricyclic thienopyridine–pyrimidones/thienopyrimidine–pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain

  摘要：

  Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the SNL pain model with ED(50)s 3.3 and 6.4 mg/kg respectively. Metabolic outcome of propargyl amino moiety was studied. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.04.104
• 作为产物：
  描述：

  Methyl 3-(dimethylaminomethylideneamino)-4-methoxythieno[2,3-b]pyridine-2-carboxylate 、 6-氨基-1,4-苯并二氧杂环 在 溶剂黄146 作用下， 以 甲苯 为溶剂， 生成 5-(2,3-Dihydro-1,4-benzodioxin-6-yl)-13-methoxy-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(13),2(7),3,9,11-pentaen-6-one
  参考文献：
  名称：

  Tricyclic thienopyridine–pyrimidones/thienopyrimidine–pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain

  摘要：

  Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the SNL pain model with ED(50)s 3.3 and 6.4 mg/kg respectively. Metabolic outcome of propargyl amino moiety was studied. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.04.104

文献信息

• mGluR1 Antagonists as therapeutic agents
  申请人：Matasi J. Julius

  公开号：US20060167029A1

  公开（公告）日：2006-07-27

  In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 4 , X, and R 1 -R 5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在许多实施方案中，本发明提供了式 I 的三环化合物（其中 J 1 -J 4 、X 和 R 1 -R 5 如本文所定义）作为代谢型谷氨酸受体（mGluR）拮抗剂，特别是作为选择性代谢型谷氨酸受体 1 拮抗剂，含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗与代谢型谷氨酸受体（如 mGluR1）相关疾病（如疼痛、偏头痛、焦虑、尿失禁和神经退行性疾病，如阿尔茨海默病）的方法。
• mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS
  申请人：Matasi Julius J.

  公开号：US20090192178A1

  公开（公告）日：2009-07-30

  In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 4 , X, and R 1 -R 5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
• US7598259B2
  申请人：——

  公开号：US7598259B2

  公开（公告）日：2009-10-06
• US7989464B2
  申请人：——

  公开号：US7989464B2

  公开（公告）日：2011-08-02
• [EN] MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS<br/>[FR] ANTAGONISTES DES MGLUR1 UTILISES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：SCHERING CORP

  公开号：WO2007070393A2

  公开（公告）日：2007-06-21

  [EN] In its many embodiments, the present invention provides tricyclic compounds of formula (I) (wherein J¹ - J⁴, X, and R¹- R⁵ are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
  [FR] La présente invention concerne, dans ses nombreuses formes de réalisation, des composés tricycliques de formule (I) ( J¹ - J⁴, X et R¹- R⁵ étant tels que définis dans le présent document) utiles en tant qu'antagonistes du récepteur du glutamate métabotropique (mGluR), en particulier en tant qu'antagonistes sélectifs du récepteur du glutamate métabotropique de type 1 ; l'invention concerne également des compositions pharmaceutiques contenant ces composés et des procédés de traitement utilisant ces composés et ces compositions pour traiter des maladies associées au récepteur du glutamate métabotropique (p. ex., le mGluR1) telles que, notamment, la douleur, la migraine, l'anxiété, l'incontinence urinaire et les maladies neurodégénératives telles que la maladie d'Alzheimer.